Get started
Author

Nickolas A. Neitzel

Observed name: N.A. Neitzel
ORCID: 0009-0000-6786-1890
Observed ORCID: 0009-0000-6786-1890
OpenAlex ID: A5062321986
SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
2023 · Alexander Drilon, Manish R. Sharma, et al. · Cancer Discovery · 75
PDF
Discovery and preclinical development of AR453588 as an anti-diabetic glucokinase activator
2019 · Ronald J. Hinklin, Brian R. Baer, et al. · Bioorganic & Medicinal Chemistry · 15
Discovery of 5-Azaquinoxaline Derivatives as Potent and Orally Bioavailable Allosteric SHP2 Inhibitors
2023 · Mohamed S. A. Elsayed, James F. Blake, et al. · ACS Medicinal Chemistry Letters · 7
PDF
Table S1 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
2023 · Alexander Drilon, Manish R. Sharma, et al. · 1
Supplementary Methods from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
2025 · Alexander Drilon, Manish R. Sharma, et al.
Table S6 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
2025 · Alexander Drilon, Manish R. Sharma, et al.
Figure S4 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
2025 · Alexander Drilon, Manish R. Sharma, et al.
Figure S7 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
2025 · Alexander Drilon, Manish R. Sharma, et al.
Table S3 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
2025 · Alexander Drilon, Manish R. Sharma, et al.
Table S9 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
2025 · Alexander Drilon, Manish R. Sharma, et al.
Table S5 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
2025 · Alexander Drilon, Manish R. Sharma, et al.
Table S8 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
2025 · Alexander Drilon, Manish R. Sharma, et al.
Figure S5 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
2025 · Alexander Drilon, Manish R. Sharma, et al.
Table S2 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
2025 · Alexander Drilon, Manish R. Sharma, et al.
Table S1 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
2025 · Alexander Drilon, Manish R. Sharma, et al.
Figure S3 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
2025 · Alexander Drilon, Manish R. Sharma, et al.
Figure S1 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
2025 · Alexander Drilon, Manish R. Sharma, et al.
Table S7 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
2025 · Alexander Drilon, Manish R. Sharma, et al.
Table S4 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
2025 · Alexander Drilon, Manish R. Sharma, et al.
Figure S6 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
2025 · Alexander Drilon, Manish R. Sharma, et al.
Figure S2 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
2025 · Alexander Drilon, Manish R. Sharma, et al.
Figure S6 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
2023 · Alexander Drilon, Manish R. Sharma, et al.
Figure S6 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
2023 · Alexander Drilon, Manish R. Sharma, et al.
Figure S4 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
2023 · Alexander Drilon, Manish R. Sharma, et al.
Table S5 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
2023 · Alexander Drilon, Manish R. Sharma, et al.
Works count: 91
Citation count: 99
H-index: 3
I10-index: 2
Year
Topic
Type